125 related articles for article (PubMed ID: 26997425)
1. Development and potential application of an oral ColoPulse infliximab tablet with colon specific release: A feasibility study.
Maurer JM; Hofman S; Schellekens RC; Tonnis WF; Dubois AO; Woerdenbag HJ; Hinrichs WL; Kosterink JG; Frijlink HW
Int J Pharm; 2016 May; 505(1-2):175-86. PubMed ID: 26997425
[TBL] [Abstract][Full Text] [Related]
2. ColoPulse tablets perform comparably in healthy volunteers and Crohn's patients and show no influence of food and time of food intake on bioavailability.
Maurer JM; Schellekens RC; van Rieke HM; Stellaard F; Wutzke KD; Buurman DJ; Dijkstra G; Woerdenbag HJ; Frijlink HW; Kosterink JG
J Control Release; 2013 Dec; 172(3):618-24. PubMed ID: 24096020
[TBL] [Abstract][Full Text] [Related]
3. Development of novel zero-order release budesonide tablets for the treatment of ileo-colonic inflammatory bowel disease and comparison with formulations currently used in clinical practice.
Gareb B; Dijkstra G; Kosterink JGW; Frijlink HW
Int J Pharm; 2019 Jan; 554():366-375. PubMed ID: 30414898
[TBL] [Abstract][Full Text] [Related]
4. Gastrointestinal pH and Transit Time Profiling in Healthy Volunteers Using the IntelliCap System Confirms Ileo-Colonic Release of ColoPulse Tablets.
Maurer JM; Schellekens RC; van Rieke HM; Wanke C; Iordanov V; Stellaard F; Wutzke KD; Dijkstra G; van der Zee M; Woerdenbag HJ; Frijlink HW; Kosterink JG
PLoS One; 2015; 10(7):e0129076. PubMed ID: 26177019
[TBL] [Abstract][Full Text] [Related]
5. Film coated tablets (ColoPulse technology) for targeted delivery in the lower intestinal tract: influence of the core composition on release characteristics.
Schellekens RC; Baltink JH; Woesthuis EM; Stellaard F; Kosterink JG; Woerdenbag HJ; Frijlink HW
Pharm Dev Technol; 2012; 17(1):40-7. PubMed ID: 20923321
[TBL] [Abstract][Full Text] [Related]
6. Formulation and pharmacokinetics of colon-specific double-compression coated mini-tablets: Chronopharmaceutical delivery of ketorolac tromethamine.
Vemula SK
Int J Pharm; 2015 Aug; 491(1-2):35-41. PubMed ID: 26056929
[TBL] [Abstract][Full Text] [Related]
7. Formulation and evaluation of multiple tablets as a biphasic gastroretentive floating drug delivery system for fenoverine.
Bandari S; Eaga CM; Thadishetty A; Yamsani MR
Acta Pharm; 2010 Mar; 60(1):89-97. PubMed ID: 20228043
[TBL] [Abstract][Full Text] [Related]
8. Gastroretentive drug delivery system of DA-6034, a new flavonoid derivative, for the treatment of gastritis.
Jang SW; Lee JW; Park SH; Kim JH; Yoo M; Na DH; Lee KC
Int J Pharm; 2008 May; 356(1-2):88-94. PubMed ID: 18276090
[TBL] [Abstract][Full Text] [Related]
9. A Novel Approach to Flurbiprofen Pulsatile Colonic Release: Formulation and Pharmacokinetics of Double-Compression-Coated Mini-Tablets.
Vemula SK
AAPS PharmSciTech; 2015 Dec; 16(6):1465-73. PubMed ID: 26017285
[TBL] [Abstract][Full Text] [Related]
10. Mini-tablets: a contemporary system for oral drug delivery in targeted patient groups.
Aleksovski A; Dreu R; Gašperlin M; Planinšek O
Expert Opin Drug Deliv; 2015 Jan; 12(1):65-84. PubMed ID: 25200881
[TBL] [Abstract][Full Text] [Related]
11. Design, development and in vitro-in vivo study of a colon-specific fast disintegrating tablet.
Kshirsagar SJ; Bhalekar MR; Umap RR
Pharm Dev Technol; 2011 Oct; 16(5):449-56. PubMed ID: 20486875
[TBL] [Abstract][Full Text] [Related]
12. Eudragit-S, Eudragit-L and cellulose acetate phthalate coated polysaccharide tablets for colonic targeted delivery of azathioprine.
Kotagale N; Maniyar M; Somvanshi S; Umekar M; Patel CJ
Pharm Dev Technol; 2010; 15(4):431-7. PubMed ID: 20236031
[TBL] [Abstract][Full Text] [Related]
13. Formulation and in-vitro evaluation of dextrin matrix tablet of Ibuprofen for colon specific drug delivery.
Salunkhe KS; Kulkarni MV
Pak J Pharm Sci; 2008 Jan; 21(1):17-20. PubMed ID: 18166513
[TBL] [Abstract][Full Text] [Related]
14. Formulation and development of release modulated colon targeted system of meloxicam for potential application in the prophylaxis of colorectal cancer.
Patel MM; Amin AF
Drug Deliv; 2011 May; 18(4):281-93. PubMed ID: 21138335
[TBL] [Abstract][Full Text] [Related]
15. Design of experiment approach for formulating multi-unit colon-targeted drug delivery system: in vitro and in vivo studies.
Shah N; Sharma OP; Mehta T; Amin A
Drug Dev Ind Pharm; 2016; 42(5):825-35. PubMed ID: 27019195
[TBL] [Abstract][Full Text] [Related]
16. [A case of refractory pediatric Crohn's disease with a successful treatment by infliximab therapy].
Park SH; Jeen YT; Chun HR; Kim DI; Baeck CW; Kim YS; Chun HJ; Lee HS; Um SH; Choi JH; Kim CD; Ryu HS; Hyun JH
Korean J Gastroenterol; 2005 Oct; 46(4):297-301. PubMed ID: 16247274
[TBL] [Abstract][Full Text] [Related]
17. Novel microbially triggered colon specific delivery system of 5-Fluorouracil: statistical optimization, in vitro, in vivo, cytotoxic and stability assessment.
Dev RK; Bali V; Pathak K
Int J Pharm; 2011 Jun; 411(1-2):142-51. PubMed ID: 21463667
[TBL] [Abstract][Full Text] [Related]
18. Development and in-vitro evaluation of a colon-specific controlled release drug delivery system.
Talukder RM; Fassihi R
J Pharm Pharmacol; 2008 Oct; 60(10):1297-303. PubMed ID: 18812022
[TBL] [Abstract][Full Text] [Related]
19. Healing of Tonsillar Crohn's Disease With Infliximab.
Bao B; Harriott M; Kroeker KI
Clin Gastroenterol Hepatol; 2017 Nov; 15(11):A31-A32. PubMed ID: 28377071
[No Abstract] [Full Text] [Related]
20. Non-coated multiparticulate matrix systems for colon targeting.
Krenzlin S; Siepmann F; Wils D; Guerin-Deremaux L; Flament MP; Siepmann J
Drug Dev Ind Pharm; 2011 Oct; 37(10):1150-9. PubMed ID: 21417601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
